Limits of Current Cancer Screening
Screening tests for cancer in general and breast, colon, lung cancers specifically have well known limitations and complience shortcomings due to their scientific limitations, invasive procedures, and expensive nature of more accurate diagnostic methods. More importantly, many of the most effective diagnostic methods remain too expensive for adoption as screening tests for all those at risk, and are used too rarely and too late stage to allow for the most effective treatment.
Blood based tests are the future of cancer screening. Todos Medical’s TBIA platform, represents a cost effective, scalable, and patient friendly screening method for cancer screening.
The TBIA Platform – Advanced Cancer Screening
Todos Medical has developed the “Total Biochemical Infrared Analysis” (TBIA) method, a proprietary method for screening of solid tumours using peripheral blood spectroscopy analysis. The process involves observing the immune system’s response to tumor presence rather than looking for the tumor cells themselves or specific markers. TBIA analyzes the entire biochemical signatures spectrum (including proteins, lipids, nucleic acids and carbohydrates) of effected immune cells from peripheral blood, using infrared spectroscopy.
- Advances in mid infrared spectroscopy (FTIR) open new diagnostic frontiers
- Immune system changes detected in plasma and mononuclear cells via FTIR
- Immune response acts as body’s sensor for cancer
- FTIR allows observation of distinct immune response to breast, colorectal, lung and other cancer types